Implant risk factors analysed - Ophthalmology Times Europe

ADVERTISEMENT

CATARACT

GLAUCOMA

REFRACTIVE

RETINA

Implant risk factors analysed


Ophthalmology Times Europe
Volume 8, Issue 4

Male gender and younger age were identified as risk factors for IOP elevation after dexamethasone implant (Ozurdex, Allergan) treatment in retinal vein occlusion (RVO) in a recent subset analysis, but the elevated IOP did not seem to affect improvement in visual acuity or anatomic outcomes evaluated with optical coherence tomography (OCT), according to Dr Michael Singer.



The subset analysis of the GENEVA study was presented as a poster by Dr Srinivas Sadda and co-authors at the annual meeting of the American Academy of Ophthalmology.

The analysis was performed to evaluate potential risk factors associated with IOP elevation after dexamethasone implant treatment and to compare the visual acuity and anatomic outcomes between patients with and without IOP elevation. It was conducted on patients who had received dexamethasone treatment in the two identical sham-controlled trials that made up the GENEVA study. This population included 298 patients with elevated IOP after single treatment or re-treatment and 535 patients without IOP elevation.

The results showed that the mean baseline age of patients with elevated IOP was 61.9 years compared with 66.4 years for those without an increase in pressure (p < 0.001). The higher rate of IOP elevation among the younger patients in the study group may be associated with hyaloid status, said Dr Singer, managing partner of Medical Center Ophthalmology Associates and assistant clinical professor, University of Texas Health Science Center at San Antonio, Texas, USA.

Dr Singer did not take part in the subset analysis but commented on the work from his perspective as a leading investigator and clinician who has extensive experience with the dexamethasone intravitreal implant.

Gender was the only other significant factor to emerge from the analysis. Males composed 67.8% of the group with elevated IOP but 43.2% of the group without (p < 0.001).

"If there are better ways to predict who is at risk or when they're at risk, it might decrease some of the apprehension that retina specialists have about using steroids," Dr Singer said.


On a scale of 1 to 10, with 1 being the lowest and 10 being the highest, how would you rate this article?
Your original vote has been tallied and is included in the ratings results.
View our top pages
Average rating for this page is: 0
WHAT DO YOU THINK?

AddThis Social Bookmark Button

Rate this article
Your comments
Discuss on our forum
Follow us on Twitter

 

Survey
Would you use topical cocaine to treat symptomatic anterior basement membrane dystrophy?
Yes
No
Yes
46%
No
54%
Source: Ophthalmology Times Europe,
Click here